Aaron Wealth Advisors LLC Reduces Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Aaron Wealth Advisors LLC has cut its holdings in Thermo Fisher Scientific Inc. by 30.6%, selling a total of 762 shares and now owning 1,726 shares valued at $700,000.
• Thermo Fisher reported a quarterly EPS of $5.36, exceeding estimates, with revenues of $10.86 billion, indicating a 2.9% increase year-over-year.
• The company declared a quarterly dividend of $0.43 per share, with an annualized yield of 0.4%, scheduled for payment on October 15th.

Aaron Wealth Advisors LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 30.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,726 shares of the medical research company's stock after selling 762 shares during the quarter. Aaron Wealth Advisors LLC's holdings in Thermo Fisher Scientific were worth $700,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of TMO. Vanguard Group Inc. raised its position in Thermo Fisher Scientific by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after acquiring an additional 230,382 shares in the last quarter. Amundi lifted its stake in Thermo Fisher Scientific by 5.9% in the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock valued at $1,426,316,000 after acquiring an additional 168,197 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Thermo Fisher Scientific by 4.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after acquiring an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA lifted its position in Thermo Fisher Scientific by 7.2% in the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after purchasing an additional 193,378 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Thermo Fisher Scientific by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after purchasing an additional 329,974 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded down $1.08 during trading on Friday, reaching $480.02. 4,241,401 shares of the company traded hands, compared to its average volume of 1,433,914. The company's 50 day moving average is $472.01 and its two-hundred day moving average is $449.50. The firm has a market capitalization of $181.26 billion, a PE ratio of 27.76, a PEG ratio of 2.56 and a beta of 0.75. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the prior year, the company posted $5.37 EPS. The company's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TMO. Raymond James Financial reissued an "outperform" rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. UBS Group raised their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Finally, Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, September 7th. Sixteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $588.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.